Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 940.22M |
| Revenue (ttm) | 94.40M |
| Net Income (ttm) | 19.66M |
| Shares Out | 35.45M |
| EPS (ttm) | 0.55 |
| PE Ratio | 47.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $26.50 |
| Previous Close | $26.08 |
| Change ($) | 0.42 |
| Change (%) | 1.61% |
| Day's Open | 25.61 |
| Day's Range | 25.36 - 26.80 |
| Day's Volume | 49,207 |
| 52-Week Range | 19.89 - 35.26 |
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel ...
PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing ...
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel thera...
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
There's a chance that it could become an even bigger success story.
SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel thera...
Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.
Investors are excited about the biotech's prospects, but the company still has a long road ahead.
Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.
About PLRX
Pliant Therapeutics, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecul... [Read more...]
| Industry Biotechnology | IPO Date Jun 3, 2020 |
| CEO Bernard Coulie | Employees 70 |
| Stock Exchange NASDAQ | Ticker Symbol PLRX |
Analyst Forecasts
According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 43.33, which is an increase of 63.51% from the latest price.